Company / SG&A Expense
Celldex Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$43.8M
FY2025
5-year range
$20.5M / $43.8M
FY2021-FY2025
Trend
+13.7%
vs FY2024
Sector context
#148 of 158
Health Care
What the data says
Among 158 Health Care companies, Celldex Therapeutics, Inc. is in the top 6% for sg&a expense. SG&A Expense has increased for 5 consecutive years, from $14M in FY2020 to $44M in FY2025.
Based on SEC 10-K filings.
$44M in FY2025 with a 5-year CAGR of +24.8%.
Increased from $31M to $44M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +17.3%
- 5-Year CAGR
- +24.8%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 158This company $43.8M Sector average $175.9B
▼
-100.0% below sector average
Key checks
Key Insights
- Celldex Therapeutics, Inc.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +24.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 13.7% year-over-year.
- Ranks #148 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $43.8M | +13.7% |
| FY2024 | $38.5M | +24.7% |
| FY2023 | $30.9M | +13.7% |
| FY2022 | $27.2M | +32.7% |
| FY2021 | $20.5M | +41.7% |
| FY2020 | $14.5M | -6.3% |
| FY2019 | $15.4M | -57.1% |
| FY2018 | $36.0M | +43.9% |
| FY2017 | $25.0M | -30.5% |
| FY2016 | $36.0M | +6.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026